Crystal Research Associates has released a 16-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

• Up to 80% of colorectal biopsies performed are subsequently identified as normal, non-cancerous tissue. Incorporating an optical biopsy, such as WavSTAT4, before performing an invasive physical biopsy reduces risks to patients by eliminating many unnecessary procedures and may lead to a healthcare cost savings of over $1 billion in the U.S. alone.

• SpectraScience is working to diagnose “pre-cancers”—suspect tissue or areas in the body before it becomes cancerous. Tissue that WavSTAT4 finds to be precancerous (or cancerous) returns a red “suspect” icon. Unlike the traditional method of visual inspection, there is no ambiguity to the result and no need for physician interpretation.

• Major 2016 corporate developments include a strategic acquisition, research publication, and development of an international sales infrastructure enabling the start of device sales in the Middle East.

Crystal Research Associates has recently released Executive Informational Overview (EIO) reports on both Ra Medical Systems, Inc., a profitable medical device company commercializing a new laser system for vascular diseases, and Biosceptre International Ltd., a development-stage immune-oncology company that has identified a new molecular target for cancer treatments.

We have just published a new set of slides that summarize the key elements of each of these companies, from business and product overviews to market sizes and growth strategies.